Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone. 

Merck Global Health Innovation Fund

Casdin Capital

D1 Capital Partners

Fidelity

aMoon Fund

ArrowMark Partners

Fidelity Management and Research Company

Perceptive Advisors

Redmile Group

Helicase Venture

Irving Investors

Absci

We’re excited to announce our new strategic partnership with PrecisionLife. Under the partnership, we’ll be working together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications. By combining our unique strengths, our goal is to create better therapies for patients with diseases that have long been challenging to treat.

Read more here: https://lnkd.in/gr3Qsp8b

#AI #Biologics #DrugDiscovery #PrecisionMedicine

For our annual Unlimiter Day this past Friday, employees from around the world gathered at our HQ in Vancouver, WA to celebrate our achievements in 2023 and plan for continued success in 2024 as we work with our new collaborators like AstraZeneca, Almirall, and PrecisionLife and continue developing our pipeline of new programs like our TL1A antibody ABS-101.

Then on Saturday, we put one of our core values, “We embrace our differences”, into action as Unlimiters volunteered with STEM Like a Girl to help build STEM kits that will be used in local schools to inspire participation in the sciences.

#AI #DrugDiscovery

Please enjoy my interview with Absci CEO Sean McClain

“We're on track to put the first de novo designed antibody with generative AI in the clinic in early 2025.”

Absci, a biotech startup using “generative AI” to create novel therapeutics, is hopefully just one year away from going into the clinic with its first design. That has already pushed Big Pharma to strike larger and larger deals with the company, says founder and CEO Sean McClain.

https://lnkd.in/eG6_MP6d

Absci
Sean McClain
#Investing #biotech #drugdevelopment #AI 

We are delighted to welcome Prof Sir Mene Pangalos to our Board of Directors and as Co-Chair of our Scientific Advisory Board. Mene brings a wealth of experience from his distinguished career, most recently as EVP of BioPharmaceuticals R&D at AstraZeneca. https://lnkd.in/grVddSSN

Apple Mobile Web Clips Icon

Google Analytics

Organization Schema

Office 365 Mail

jsDelivr

Wordpress Plugins

Yoast WordPress SEO Plugin

Cloudflare DNS

jQuery CDN

Amazon SSL

Scientist I

George Sellhorn

Chief Financial Officer

Greg Schiffman

Chief Marketing Officer

Jack Gold

Chief Technology Officer

Matthew Weinstock

Chief Legal Officer

Sarah Korman

Founder & CEO

Sean McClain

VP of Immunology

Daniele Biasci

SVP Target & Antibody Discovery

Deniz Kural

VP AI Research

Gregory Hannum

VP, Business Development

Imad Ajjawi

Andreas Busch

Zach Jonasson

Dan Gold

Bryan Lawlis

Denise Dettore

Chief People Officer

Dan Rabinovitsj

Independent Director

Chief Innovation Officer

Founder, Director & CEO

VP of Business Development

United States Companies With Less Than $1B in Revenue (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Washington Companies With More Than 50 Employees

Companies With More Than $1M in Revenue (Top 10K)

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

Post-IPO Equity - Absci

Venture Round - Absci

Corporate Round - Absci

Series E - Absci

JSR Life Sciences

KBI Biopharma

Series D - Absci

Debt Financing - Absci

Series C - Absci

Phoenix Venture Partners

Series B - Absci

Series A - Absci

Computer and Software Services and Scientific Services

Vancouver

Washington

United States

North America

Tech Layoffs: US Companies That Cut Jobs In 2022, 2023 And 2024

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Cathie Wood's ARK Investment bought 94.4K shares of Absci today

Absci and Twist Bioscience Team Up to Redefine Antibody Discovery with AI

Cathie Wood's ARK Investment bought 401K shares of Absci today

Treasury Market Summary:

ABGSC to publish Q3 2024 Interim Report on 17 October

Absci reports Q EPS (22c), consensus (19c)

AI antibody generator Absci inks cancer collaboration with Memorial Sloan Kettering

A platform combining AI with synthetic biology to design, test, and validate new biologic-based therapeutics, enabling rapid drug creation from AI-designed antibodies to wet lab-validated candidates.

A process that generates a library of sequence variants to establish target specificity, creating novel lead drug candidates with desirable attributes.

A multiparametric AI approach to evaluate and optimize antibody variants for improved target affinity, manufacturability, and other pharmacologic characteristics.

A method to reconstruct immune-response molecules from disease tissue and identify their corresponding antigens, offering new therapeutic targets and binding partners for further validation and optimization.

A synthetic biology approach that constructs billions of genetically-distinct cells to produce and evaluate protein variants, providing high-quality data to train AI models.

United Kingdom

Europe

Bangladesh

Asia

France

India

HTML5

Gravity Forms

Office 365

Wordpress

Cloudflare CDN

jQuery

Vimeo

Microsoft Outlook

Modernizr

Bootstrap

TScan focuses on developing novel TCR-engineered T cell therapies for the treatment of cancer.

TScan

3T is a company specializing in advanced technologies for drug discovery and development.

Schrodinger is a leading provider of advanced molecular simulations and drug discovery software.

Schrodinger

Arcellx is a biotechnology company focused on developing novel cell therapies for cancer treatment.

Arcellx

NGM Biopharmaceuticals is dedicated to discovering and developing innovative therapeutics for various diseases.

NGM Biopharmaceuticals

Principia Biopharma focuses on developing small molecule therapeutics for immune-mediated diseases.

Principia Biopharma

Absci Corporation is a generative AI drug creation company that operates in the United States. The company's integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates using generative AI and synthetic biology. Absci aims to create better biologics for patients, faster, by unlocking the potential of generative AI and enabling a shift from drug discovery to drug creation.

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

news impact assignment basic	general	Feb 21, 2024 3:31 PM	7e43202d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 21, 2024 3:31 PM	f7ce47c7
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	db23517a
crunchbase profile	general	Nov 22, 2024 9:30 AM	8dc08704
li profile	general	Feb 21, 2024 3:31 PM	124956d6
translate crunchbase fundingrounds	general	Nov 22, 2024 1:53 PM	270aa307
peers	general	Feb 21, 2024 3:31 PM	155e04b5
news basic	general	Feb 21, 2024 3:31 PM	8cbb30af
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ABSCI

Absci Corporation

Last Close

2.55

22/11 21:00

Market Cap

408.23M

Beta: -

Volume Today

1.09M

Avg: -